- (II) \$20 FOR A PRESCRIPTION FOR A PREFERRED BRAND NAME DRUG; AND
- (III) \$35 FOR A PRESCRIPTION FOR A NONPREFERRED BRAND NAME DRUG.
- (B) THE BOARD MAY LIMIT THE TOTAL ANNUAL BENEFIT TO \$1,000 PER INDIVIDUAL.
- (C) (1) THE BOARD, BY REGULATION, SHALL ADOPT A PRESCRIPTION DRUG FORMULARY FOR THE PROGRAM.
- (2) THE BOARD MAY EXCLUDE FROM THE PROGRAM'S FORMULARY ANY EXPERIMENTAL DRUG THAT IS NOT APPROVED BY THE FEDERAL FOOD AND DRUG ADMINISTRATION FOR GENERAL USE SUBJECT TO APPROVAL BY THE BOARD, THE CARRIER THAT ADMINISTERS THE PROGRAM SHALL DEVELOP A PRESCRIPTION DRUG FORMULARY TO BE USED IN THE PROGRAM.

14-513.

- (A) PREMIUMS COLLECTED FOR THE PROGRAM SHALL BE DEPOSITED TO A SEGREGATED ACCOUNT IN THE FUND ESTABLISHED UNDER § 14–504 OF THIS SUBTITLE.
- (B) IN ADDITION TO PREMIUM INCOME, THE SEGREGATED ACCOUNT SHALL INCLUDE:
- (I) INTEREST AND INVESTMENT INCOME ATTRIBUTABLE TO PROGRAM FUNDS; AND
- (II) MONEY DEPOSITED TO THE ACCOUNT BY THE CARRIER THAT ADMINISTERS THE PROGRAM IN ACCORDANCE WITH SUBSECTION (C) OF THIS SECTION.
- (C) (1) BY JUNE-30 OF EACH YEAR, ON OR BEFORE APRIL 1, 2003 AND QUARTERLY THEREAFTER, THE PROGRAM ADMINISTRATOR SHALL DEPOSIT TO THE FUND UNDER § 14–504 OF THIS SUBTITLE:
 - (I) PREMIUMS COLLECTED; AND
- (II) THE AMOUNT, IN EXCESS OF PREMIUMS COLLECTED, THAT IS NECESSARY TO OPERATE AND ADMINISTER THE PROGRAM FOR THE $\frac{12}{12}$ MONTHS FOLLOWING QUARTER.
- (2) THE AMOUNT DEPOSITED SHALL BE DETERMINED BY THE BOARD BASED ON ENROLLMENT, EXPENDITURES, AND REVENUE FOR THE PREVIOUS YEAR.
- (3) THE AMOUNT REQUIRED BY THE BOARD UNDER PARAGRAPH (2) OF THIS SUBSECTION MAY NOT EXCEED THE VALUE OF THE PROGRAM ADMINISTRATOR'S ANNUAL PREMIUM TAX EXEMPTION UNDER § 6–101(B) OF THIS ARTICLE.